| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/19/2001 | EP1133484A2 Heterocyclic derivatives and their use as integrin inhibitors |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133467A1 Ion channel modulating agents |
| 09/19/2001 | EP1133312A2 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133279A1 Method of producing vitamin powders |
| 09/19/2001 | EP0918536B1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 09/19/2001 | EP0869954B1 Heterocyclic compounds for use in the treatment of neurogenic inflammation |
| 09/19/2001 | CN1313866A Method for chromatographically purifying insulins |
| 09/19/2001 | CN1313862A Novel 17-halogenated 19-Nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | CN1313856A Thiazoline acid derivatives |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1313128A Chinese-medicinal capsule for treating diabetes and its preparing process |
| 09/19/2001 | CN1313122A Medicine for treating diabetes |
| 09/19/2001 | CN1313119A Medicinal particles for treating diabetic peripheral neuropathy |
| 09/19/2001 | CN1313118A Hypoglycemic capsule |
| 09/19/2001 | CN1313091A Bone strengthening capsules of Biyang yak bone marrow |
| 09/19/2001 | CN1313089A Iron-supplementing instant effervescent particles and its preparing process |
| 09/19/2001 | CN1313085A Application of cinnamic acid in controlling morbility of I-type diabetes |
| 09/19/2001 | CN1313048A Health-care product for reducing blood fat and sugar and delaying sanility |
| 09/19/2001 | CN1071333C Quinoline derivative |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071318C Ortho-substd. benzoyl guanidines, their preparing process and use as medicine and diagnostic reagent, and medicine contg. same |
| 09/19/2001 | CN1071120C Medicines for disease characterized by polydipsia, polyphagia and polyuria |
| 09/18/2001 | US6291657 N-butyldeoxygalactonojirimycin; suppression of glycolipid biosynthesis; microbiocides; treatment of gaucher's disease |
| 09/18/2001 | US6291522 Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 09/18/2001 | US6291495 Insulin sensitizer; and a sulfonylurea, a biguanide, or an alpha-glucosidase inhibitor. |
| 09/18/2001 | US6291491 Treatment of type ii diabetes and obesity; antidepressants; decrease gut motility. |
| 09/18/2001 | US6291489 Process for substituted pyridines |
| 09/18/2001 | US6291486 Polycyclic Dihydrothiazoles, their preparation and use as pharmaceuticals |
| 09/18/2001 | US6291477 Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia |
| 09/18/2001 | US6291473 Treating anxiety, depression, post-traumatic stress disorder, inflammatory diseases, obesity, in mammals |
| 09/18/2001 | US6291459 Calcilytic compounds |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | CA2145182C Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| 09/18/2001 | CA2045783C 9-purinyl phosphonic acid derivatives |
| 09/18/2001 | CA2026890C Quinoline derivatives, their production and use |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066714A1 α-AMYLASE ACTIVITY INHIBITORS |
| 09/13/2001 | WO2001066607A1 Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| 09/13/2001 | WO2001066606A1 Crosslinked anion-exchange resin or salt thereof |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066553A2 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066533A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | WO2001066531A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | WO2001066521A1 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 09/13/2001 | WO2001066146A1 Methods and compositions for dietary supplements |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066135A1 Lowering serum lipids |
| 09/13/2001 | WO2001066133A1 Leptin-resistance ameliorating agents |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066098A2 Therapeutic uses of ppar mediators |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | WO2000063370A3 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 09/13/2001 | WO2000059886A3 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021719 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents |
| 09/13/2001 | US20010021708 Acylurea compound containing imidazolidine ring |
| 09/13/2001 | US20010021696 Administering hormonally inactive insulin or analogue; selectively inhibits beta-cell destructive immune responses without inducing insulin inherent side effects |
| 09/13/2001 | US20010021694 Treating bulimia and eating disorders, stimulating cholecystokinin, protein powder with glycomacropeptide or casein, fatty acid, fiber |
| 09/13/2001 | US20010021526 Immortal rho degrees cell line; undifferentiated cells for drug screening; alzheimers, huntington's disease, myoclonic epilepsy lactic acidosis and stroke (MELAS); myoclonic epilepsy ragged red fiber (MERRF) |
| 09/13/2001 | US20010021510 Materials and methods for detection and treatment of immune system dysfunctions |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2402315A1 Therapeutic uses of ppar mediators |
| 09/13/2001 | CA2402273A1 Methods and compositions for dietary supplements |
| 09/13/2001 | CA2401953A1 Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase |
| 09/13/2001 | CA2401706A1 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401055A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/12/2001 | EP1132404A2 Acylated insulin |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1132382A1 3-Oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/12/2001 | EP1132092A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 09/12/2001 | EP1132088A2 Method for inhibiting bone resorption |
| 09/12/2001 | EP1132087A1 Remedies for polycystic ovary syndrome |
| 09/12/2001 | EP1132083A2 Use of zinc tranexamate in the treatment of diabetes |